Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow

David G. Kiely, Robin Condliffe
European Respiratory Journal 2021 58: 2102008; DOI: 10.1183/13993003.02008-2021
David G. Kiely
1Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
2Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
3INSIGNEO, Institute for In Silico Medicine, University of Sheffield, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David G. Kiely
  • For correspondence: david.kiely1@nhs.net
Robin Condliffe
1Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
2Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robin Condliffe
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In patients with lung disease and pulmonary hypertension, measures of resistance (pulmonary vascular resistance) and not flow (cardiac index) should be used to assess for severe pulmonary hypertension https://bit.ly/3xaL0mk

Introduction

Managing patients with pulmonary hypertension (PH) in association with chronic lung disease and/or hypoxia (PH-CLD) remains one of the most challenging areas in pulmonary vascular medicine. Its presence in COPD and interstitial lung disease (ILD) impacts negatively on symptoms and survival [1, 2], predicts more frequent exacerbations [3] and has the worst prognosis of all forms of PH [4]. In contrast to treatment advances seen in other forms of PH, for the majority of patients with PH-CLD, treatment remains aimed at the underlying lung disease, including lung transplantation in suitable patients. One of the major challenges to evaluating new therapies in PH-CLD relates to the heterogeneity of pulmonary vascular involvement.

Identifying patients with PH-CLD with a pulmonary vascular phenotype

Severe PH occurs in a minority of patients with lung disease [1, 5]; however, estimates of its prevalence suggest it is several-fold more common than group 1 PH, pulmonary arterial hypertension (PAH) [6]. Studies that improve our understanding of PH-CLD and aid classification and patient selection for therapeutic trials are therefore urgently needed. In this edition of the European Respiratory Journal, studies by Zeder et al. [7] and Olsson et al. [8] take us a step further by providing evidence-based pulmonary haemodynamic thresholds that more accurately identify patients with severe PH who are most likely to have a pulmonary vascular phenotype [9]. In doing so they challenge current haemodynamic thresholds for severe PH and highlight that a measure of resistance and not flow best predicts mortality in both COPD and ILD. They also remind us that PH is a haemodynamic diagnosis and can occur in the absence of pulmonary vascular involvement. In lung disease in particular, elevations in intrathoracic pressure and cardiac output commonly cause mild to moderate PH without significant pulmonary vascular disease. Excluding such patients from trials of PAH therapies would seem logical as would enriching studies for populations with pulmonary vascular remodelling where such therapies would be expected to have most benefit.

Is it time to update the definition for haemodynamic severity in PH-CLD?

The 2015 European Society of Cardiology/European Respiratory pulmonary hypertension guidelines defined severe PH as a mean pulmonary arterial pressure (mPAP) ≥35 mmHg or a mPAP ≥25 mmHg with a cardiac index (CI) of <2.5 L·min−1·m−2, not explained by other causes [10]. Reflecting data that a mPAP >20 mmHg is abnormal, the 6th World Symposium [11] defined PH-CLD as mPAP 21–24 mmHg and pulmonary vascular resistance (PVR) ≥3 WU or mPAP 25–34 mmHg and severe PH-CLD as mPAP ≥35 mmHg or mPAP ≥25 mmHg with a CI <2.0 L·min−1·m−2. As both Zeder et al. [7] and Olsson et al. [8] highlight, the choice of cut-off values of haemodynamic severity, including measures of flow, namely CI, were arbitrary and based on expert opinion.

Zeder et al. [7] noted that both mPAP and PVR, but not CI, were associated with survival in 139 patients with COPD, after adjustment for age, sex and forced expiratory volume in 1 s. Using an unbiased approach, of all haemodynamic measurements, a PVR >5 WU was the best prognostic cut-off. Two equivalent mPAP thresholds were identified: one of 33 mmHg (similar to current definitions) and a second of 40 mmHg (previously identified by the ASPIRE Registry [12]). Whereas a PVR >5 WU was rare in the absence of mPAP ≥33 mmHg (4%), an mPAP ≥33 mmHg with a PVR ≤5 WU was associated with more severe pulmonary disease and left heart disease.

Olsson et al. [8] adopted a similar approach in patients with ILD. In a large, well-characterised cohort from the COMPERA registry of 449 patients with ILD, age, sex and higher PVR, but not mPAP or CI, predicted survival [8]. A PVR >5 WU was associated with a significantly worse survival compared to a PVR ≤5 WU, although a PVR >8 WU had the lowest p-value and was a better discriminator of survival. Importantly, the currently proposed haemodynamic definition of severe PH did not distinguish between survivors and non-survivors. Both these studies illustrate that it is a measure of resistance and not flow that is key in defining disease severity in PH-CLD. Figure 1 incorporates the findings of the studies by Zeder et al. [7] and Olssen et al. [8] in a proposed new haemodynamic definition for PH and severe PH in CLD, and how it could be used to enrich PAH therapy trials for patients most likely to have a pulmonary vascular phenotype and a circulatory rather than ventilatory limit to exercise.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Evidence based haemodynamic definition for pulmonary hypertension (PH) severity in lung disease to enrich for a pulmonary vascular phenotype in pulmonary arterial hypertension (PAH) therapy trials. DLCO: diffusing capacity of the lung for carbon monoxide; ABG: arterial blood gas; NT-proBNP: N-terminal-pro-B-type-natriuretic peptide; CTPA: computed tomography pulmonary angiography; mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; RCT: randomised controlled trial.

PAH therapies in ILD

A number of randomised controlled trials of PAH therapies in patients with ILD and COPD have been performed (table 1). The endothelin receptor antagonists bosentan, ambrisentan and macitentan were found to have no effect on idiopathic pulmonary fibrosis (IPF) progression in patients at low risk of having PH and ambrisentan was associated with worse outcomes [13–15]. The BPHIT trial subsequently studied the effects of bosentan in patients with IPF or fibrotic idiopathic non-specific interstitial pneumonia and significant PH (mPAP 37 mmHg and PVR 7.4 WU) and observed no significant effect on pulmonary haemodynamics, exercise capacity or quality of life [16]. A post hoc analysis of patients from the STEP-IPF trial suggested a stabilisation of 6-min walk distance (6MWD) and improvement in quality of life in those patients with right ventricular (RV) dysfunction who received sildenafil [17]. Two subsequent studies of sildenafil in patients with IPF receiving background antifibrotic therapy were therefore performed but failed to reach their primary endpoints [18, 19]. The INSTAGE study [18] in patients receiving nintedanib included 45% of patients with RV dysfunction on echocardiography, while in the study of Behr et al. [19] in patients receiving pirfenidone, the mean systolic pulmonary arterial pressure (sPAP) at echocardiography was 56 mmHg and mPAP 27 mmHg in 18% of patients undergoing right heart catheterisation (RHC). Of note, a subgroup analysis of the INSTAGE study demonstrated beneficial effects of sildenafil on N-terminal-pro-B-type-natriuretic peptide (NT-proBNP) levels in patients with RV dysfunction on echocardiography [20]. The RISE-IIP study assessed riociguat in patients with idiopathic interstitial pneumonias and RHC-proven PH (mPAP 33 mmHg and PVR 4.9 WU) [21]. The study was terminated early due to an increased incidence of severe adverse events, including deaths, in patients receiving riociguat. The INCREASE study assessed the benefits of inhaled treprostinil, a prostacyclin analogue, in patients with fibrotic lung disease and PH demonstrated at RHC (mPAP 37 mmHg and PVR 6.4 WU) [22]. Significant effects on 6MWD, NT-proBNP and clinical worsening were observed in patients receiving treprostinil. Interestingly, subgroup analysis revealed that beneficial effects were seen in patients with a PVR ≥4 WU but not in those with a PVR <4 WU.

View this table:
  • View inline
  • View popup
TABLE 1

Key randomised controlled trials of pulmonary hypertension (PH) therapies in interstitial lung disease (ILD) and COPD

PAH therapies in COPD

The effects of PAH therapies have also been assessed in a number of randomised controlled trials (RCTs) in patients with COPD (table 1) [23–26]. Studies of bosentan [23], sildenafil [24] and tadalafil [25] in populations enriched for PH but with echocardiographic evidence of modest PH have failed to meet their primary endpoints. The SPHERIC-1 trial [26] enrolled a small number of patients with more severe RHC-proven PH (mPAP 39 mmHg and PVR 7 WU), and demonstrated significant improvements in PVR and quality of life.

Improving outcomes for patients with PH-CLD: refining patient phenotyping

What, then, can we learn from the published RCT data of PAH therapies in PH-CLD? Can improvements in how we phenotype and evaluate patients translate into improved outcomes? First, some therapies have been associated with adverse outcomes, reinforcing the need for careful assessment of the risk–benefit ratio for treatment in individual patients. Second, published studies highlight the need for further RCTs to identify patient phenotypes who may benefit from PAH therapies. A significant number of studies have relied on diffusing capacity of the lung for carbon monoxide and echocardiography to enrich studied populations for the presence of PH. Patients in these trials have, on the whole, had evidence of modest PH and all studies failed to reach their primary endpoints. The studies by Zeder et al. [7] and Olssen et al. [8] highlight the importance of comprehensive haemodynamic characterisation in the assessment of patients with PH-CLD and support future RCTs of PAH therapies in lung disease enrolling patients who have undergone haemodynamic assessment using RHC. Third, RCTs published to date suggest that certain therapies (endothelin receptor antagonists in ILD) and certain phenotypes (mild PH where exercise limitation is more likely to be due to respiratory rather than pulmonary vascular disease) [27] are not associated with beneficial treatment responses in PH-CLD. Previous open-label studies have reported haemodynamic and functional response to sildenafil and prostacyclin analogues in patients with ILD and severe elevations in mPAP and PVR [28, 29], while clinical response to predominantly phosphodiesterase-5 inhibitor-based therapy has been associated with improved survival in patients with severe PH associated with COPD [12, 30]. Finally, in addition to refining haemodynamic severity of PH-CLD, advances in imaging technology using quantitative computed tomography and the application of artificial intelligence technologies may allow more detailed assessment of the extent of parenchymal and vascular involvement in CLD [31]. Magnetic resonance imaging, the gold standard for cardiac assessment, predicts mortality and clinical worsening in PAH [32], can identify patients with severe PH-COPD [33] and is highly sensitive to treatment effect in patients with PAH [34, 35], and may be a future endpoint for clinical trials of PAH therapies in CLD.

Conclusion

In summary, these data suggest that future RCTs of PAH therapies are warranted in PH-CLD but should enrol well-characterised patients with more severe PH. This issue of the European Respiratory Journal suggests that the optimal threshold for defining this haemodynamic state is a PVR >5 WU.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-02008-2021.Shareable

Footnotes

  • Conflict of interest: D.G. Kiely reports grants, personal fees and funds for meeting attendance from Janssen and GSK, personal fees and funds for meeting attendance from MSD, personal fees from Acceleron, outside the submitted work.

  • Conflict of interest: R. Condliffe reports personal fees and funds for meeting attendance from Janssen, GSK and MSD, outside the submitted work.

  • Received July 19, 2021.
  • Accepted July 21, 2021.
  • Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Lettieri CJ,
    2. Nathan SD,
    3. Barnett SD, et al.
    Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746–752. doi:10.1378/chest.129.3.746
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Medrek SK,
    2. Sharafkhaneh A,
    3. Spiegelman AM, et al.
    Admission for COPD exacerbation is associated with the clinical diagnosis of pulmonary hypertension: results from a retrospective longitudinal study of a veteran population. COPD 2017; 14: 484–489. doi: 10.1080/15412555.2017.1336209
    OpenUrl
  3. ↵
    1. Wells JM,
    2. Washko GR,
    3. Han MK, et al.
    Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367: 913–921. doi: 10.1056/NEJMoa1203830
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Hurdman J,
    2. Condliffe R,
    3. Elliot CA, et al.
    ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39: 945–955. doi: 10.1183/09031936.00078411
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Chaouat A,
    2. Bugnet AS,
    3. Kadaoui N, et al.
    Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189–194. doi:10.1164/rccm.200401-006OC
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Olschewski H
    . The challenge to decide between pulmonary hypertension due to chronic lung disease and PAH with chronic lung disease. Diagnostics (Basel) 2021; 11: 311. doi: 10.3390/diagnostics11020311
    OpenUrl
  7. ↵
    1. Zeder K,
    2. Avian A,
    3. Bachmaier G, et al.
    Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58: 2100944.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Olsson KM,
    2. Hoeper MM,
    3. Pausch C, et al.
    Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021; 58: 2101483.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Kovacs G,
    2. Agusti A,
    3. Barberà JA, et al.
    Pulmonary vascular involvement in chronic obstructive pulmonary disease. is there a pulmonary vascular phenotype? Am J Respir Crit Care Med 2018; 198: 1000–1011. doi: 10.1164/rccm.201801-0095PP
    OpenUrl
  10. ↵
    1. Galiè N,
    2. Humbert M,
    3. Vachiery JL, et al.
    2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015; 46: 903–975. doi: 10.1183/13993003.01032-2015
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Nathan SD,
    2. Barbera JA,
    3. Gaine SP, et al
    . Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53: 1801914. http://dx.doi.org/10.1183/13993003.01914-2018.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Hurdman J,
    2. Condliffe R,
    3. Elliot CA, et al.
    Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41: 1292–1301. doi: 10.1183/09031936.00079512
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. King TE Jr.,
    2. Brown KK,
    3. Raghu G, et al.
    BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92–99. doi:10.1164/rccm.201011-1874OC
    OpenUrlCrossRefPubMedWeb of Science
    1. Raghu G,
    2. Behr J,
    3. Brown KK, et al.
    Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641–649. doi:10.7326/0003-4819-158-9-201305070-00003
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Raghu G,
    2. Million-Rousseau R,
    3. Morganti A, et al.
    Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013; 42: 1622–1632. doi:10.1183/09031936.00104612
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Corte TJ,
    2. Keir GJ,
    3. Dimopoulos K, et al.
    Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2014; 190: 208–217. doi:10.1164/rccm.201403-0446OC
    OpenUrlCrossRefPubMed
  16. ↵
    1. Han MK,
    2. Bach DS,
    3. Hagan PG, et al.
    Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013; 143: 1699–1708. doi:10.1378/chest.12-1594
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Kolb M,
    2. Raghu G,
    3. Wells AU, et al.
    Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med 2018; 379: 1722–1731. doi:10.1056/NEJMoa1811737
    OpenUrlPubMed
  18. ↵
    1. Behr J,
    2. Nathan SD,
    3. Wuyts WA, et al.
    Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9: 85–95. doi:10.1016/S2213-2600(20)30356-8
    OpenUrl
  19. ↵
    1. Behr J,
    2. Kolb M,
    3. Song JW, et al.
    Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction. A prespecified subgroup analysis of a double-blind randomized clinical trial (INSTAGE). Am J Respir Crit Care Med 2019; 200: 1505–1512. doi:10.1164/rccm.201903-0488OC
    OpenUrlPubMed
  20. ↵
    1. Nathan SD,
    2. Behr J,
    3. Collard HR, et al.
    Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019; 7: 780–790. doi:10.1016/S2213-2600(19)30250-4
    OpenUrl
  21. ↵
    1. Waxman A,
    2. Restrepo-Jaramillo R,
    3. Thenappan T, et al.
    Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 2021; 384: 325–334. doi:10.1056/NEJMoa2008470
    OpenUrlPubMed
  22. ↵
    1. Stolz D,
    2. Rasch H,
    3. Linka A, et al.
    A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619–628. doi:10.1183/09031936.00011308
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Blanco I,
    2. Santos S,
    3. Gea J, et al.
    Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013; 42: 982–992. doi:10.1183/09031936.00176312
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Goudie AR,
    2. Lipworth BJ,
    3. Hopkinson PJ, et al.
    Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2014; 2: 293–300. doi:10.1016/S2213-2600(14)70013-X
    OpenUrl
  25. ↵
    1. Vitulo P,
    2. Stanziola A,
    3. Confalonieri M, et al.
    Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial. J Heart Lung Transplant 2017; 36: 166–174. doi:10.1016/j.healun.2016.04.010
    OpenUrl
  26. ↵
    1. Boerrigter BG,
    2. Bogaard HJ,
    3. Trip P, et al.
    Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012; 142: 1166–1174. doi:10.1378/chest.11-2798
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Ghofrani HA,
    2. Wiedemann R,
    3. Rose F, et al.
    Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895–900. doi:10.1016/S0140-6736(02)11024-5
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Olschewski H,
    2. Ghofrani HA,
    3. Walmrath D, et al.
    Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600–607. doi:10.1164/ajrccm.160.2.9810008
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Vizza CD,
    2. Hoeper MM,
    3. Huscher D, et al.
    Pulmonary hypertension in patients with COPD: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Chest 2021; 160: 678–689.
    OpenUrl
  30. ↵
    1. Dwivedi K,
    2. Sharkey M,
    3. Condliffe R, et al.
    Pulmonary hypertension in association with lung disease: quantitative CT and artificial intelligence to the rescue? State-of-the-Art Review. Diagnostics (Basel) 2021; 11: 679. doi: 10.3390/diagnostics11040679
    OpenUrl
  31. ↵
    1. Alabed S,
    2. Shahin Y,
    3. Garg P, et al.
    Cardiac-MRI predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2021; 14: 931–942. doi: 10.1016/j.jcmg.2020.08.013
    OpenUrl
  32. ↵
    1. Johns CS,
    2. Rajaram S,
    3. Capener DA, et al.
    Non-invasive methods for estimating mPAP in COPD using cardiovascular magnetic resonance imaging. Eur Radiol 2018; 28: 1438–1448. doi: 10.1007/s00330-017-5143-y
    OpenUrl
  33. ↵
    1. Swift AJ,
    2. Wilson F,
    3. Cogliano M, et al.
    Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. Thorax 2021; in press [https://doi.org/10.1136/thoraxjnl-2020-216078]. doi: 10.1136/thoraxjnl-2020-216078
  34. ↵
    1. Kiely DG,
    2. Channick R,
    3. Flores D, et al.
    Comparison of standardized treatment effect sizes for invasive and non-invasive endpoints in pulmonary arterial hypertension: insights from the REPAIR study. JACC 2021; 77: 1672. doi:10.1016/S0735-1097(21)03028-X
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 58 Issue 2 Table of Contents
European Respiratory Journal: 58 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow
David G. Kiely, Robin Condliffe
European Respiratory Journal Aug 2021, 58 (2) 2102008; DOI: 10.1183/13993003.02008-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow
David G. Kiely, Robin Condliffe
European Respiratory Journal Aug 2021, 58 (2) 2102008; DOI: 10.1183/13993003.02008-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Introduction
    • Identifying patients with PH-CLD with a pulmonary vascular phenotype
    • Is it time to update the definition for haemodynamic severity in PH-CLD?
    • PAH therapies in ILD
    • PAH therapies in COPD
    • Improving outcomes for patients with PH-CLD: refining patient phenotyping
    • Conclusion
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Addressing the effect of ancestry on lung volume
  • Consensus statement on quality standards for managing children with bronchiectasis
  • Bronchodilators in bronchiectasis: there is light but it is still too dim
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society